Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Sep 20;3(2):132–137. doi: 10.1111/j.2040-1124.2011.00160.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd

PMC Copyright notice

Effect of therapeutic administration of FTY720 alone or in combination with insulin glargine on (a) the ratio of insulin‐positive β‐cells/total islet area and (b) the extent of insulitis in NOD mice with overt type 1 diabetes mellitus (DM). Representative pictures illustrating the different insulitis scores are also shown (b). Female NOD mice with hyperglycemia (i.e. with overt DM) were treated for 70 days with: 0.1 mg/kg, p.o., FTY720 twice a week plus insulin glargine (for dosing, refer to Materials and Methods; n = 4; □); 0.1 mg/kg, p.o., FTY720 twice a week (n = 4; ); 1.0 IU, s.c., insulin glargine once daily, (n = 4; ▮). Pancreas sections were obtained after the observation period (70 days) from mice in each of the three groups, as well as from age‐matched NOD mice with normoglycemia (n = 4; ) and stained with monoclonal rat anti‐insulin antibody or with hematoxylin–eosin. Data are the mean ± SD. The significance of differences was determined by the Mann–Whitney U‐test.

Inline graphic — Effect of therapeutic administration of FTY720 alone or in combination with insulin glargine on (a) the ratio of insulin‐positive β‐cells/total islet area and (b) the extent of insulitis in NOD mice with overt type 1 diabetes mellitus (DM). Representative pictures illustrating the different insulitis scores are also shown (b). Female NOD mice with hyperglycemia (i.e. with overt DM) were treated for 70 days with: 0.1 mg/kg, p.o., FTY720 twice a week plus insulin glargine (for dosing, refer to Materials and Methods; n = 4; □); 0.1 mg/kg, p.o., FTY720 twice a week (n = 4; ); 1.0 IU, s.c., insulin glargine once daily, (n = 4; ▮). Pancreas sections were obtained after the observation period (70 days) from mice in each of the three groups, as well as from age‐matched NOD mice with normoglycemia (n = 4; ) and stained with monoclonal rat anti‐insulin antibody or with hematoxylin–eosin. Data are the mean ± SD. The significance of differences was determined by the Mann–Whitney U‐test.